Mizuho initiated coverage of Eikon Therapeutics (EIKN) with an Outperform rating and $26 price target The firm says the company’s single-molecule tracking platform represents a “novel and differentiated” approach to drug discovery that has the opportunity to accelerate discovery timelines and potentially increase probabilities of clinical success.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EIKN:
- Eikon Therapeutics initiated with an Overweight at JPMorgan
- Eikon Therapeutics initiated with an Overweight at Morgan Stanley
- Spotify upgraded, First Solar downgraded: Wall Street’s top analyst calls
- Wedbush starts Eikon at Underperform on ‘significant clinical risk’
- Eikon Therapeutics initiated with an Underperform at Wedbush